Resistance to imatinib of Bcr/Abl P190 lymphoblastic leukemia cells

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5387-5393

  Mishra, Suparna ^a   Zhang, Bin ^a   Cunnick, Jess M ^a   Heisterkamp, Nora ^a   Groffen, John ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; IMATINIB; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER TRANSPLANTATION; CELL CONTACT; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG SENSITIVITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; STROMA CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHEMOKINES, CXC; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC; MICE; MICE, NUDE; PIPERAZINES; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; STROMAL CELLS;

EID: 33744913814     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3058     Document Type: Article

References (50)

1. Heisterkamp N, Groffen J. BCR/ABL gene structure and BCR function. In: Carella AM, Daley GQ, Eaves CM, Goldman JM, Hehlman R, editors. Chronic myeloid leukemia: biology and treatment. United Kingdom: Martin Dunitz Ltd.; 2001. p. 3-17.
2. Faderl S, Garcia-Manero G, Thomas DA, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia-current concepts and future perspectives. Rev Clin Exp Hematol 2002;6:142-60.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
4. Johnson JR, Bross P, Cohen M, et al. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003;9:1972-9.
5. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
6. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of Imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
7. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95:1758-66.
8. Scappini B, Gatto S, Onida F, et al. Changes associated with the development of resistance to Imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004;100:1459-71.
9. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to Imatinib. Semin Hematol 2003;40:69-79.
10. Ricci C, Scappini B, Divoky V, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002;62:5995-8.
11. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
12. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99:1860-2.
13. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.
14. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to Imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-73.
15. Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002;359:481-6.
16. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-61.
17. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8.
18. Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to Imatinib mesylate. Exp Hematol 2003;31:1073-80.
19. Voncken J-W, Griffiths S, Greaves MF, et al. Restricted oncogenicity of BCR/ABL P190 in transgenic mice. Cancer Res 1992;52:4534-9.
20. Mishra S, Reichert A, Cunnick J, et al. Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003;22:8255-62.
21. Mishra S, Zhang B, Groffen J, et al. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia 2004;18:23-8.
22. Rolink A, Melchers F. Molecular and cellular origins of B lymphocyte diversity. Cell 1991;66:1081-94.
23. Chen EY, Swanson BJ, Clark SS. Transformation of undifferentiated Thy-Ilo B220+ thymic lymphoid cells by the Abelson murine leukemia virus. Dev Immunol 2000;8: 1-18.
24. von Bubnoff N, Veach DR, van der Kuip H, et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005;105: 1652-9.
25. Sacha T, Hochhaus A, Hanfstein B, et al. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk Res 2003;27:1163-6.
26. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991;173:1213-25.
27. Li YS, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med 1993;178:951-60.
28. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
29. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
30. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to Imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
31. Gargallo P, Hagemeijer A, Vassallu P, et al. Insertion (4;11)(q27;q24q21) in a patient with essential thrombocythemia with progression to myelofibrosis. Cancer Genet Cytogenet 2004;154:72-6.
32. Wognum AW, Eaves AC, Thomas TE. Identification and isolation of hematopoietic stem cells. Arch Med Res 2003;34:461-75.
33. Beattie GM, Lopez AD, Bucay N, et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 2005; 23:489-95.
34. Wang L, Li L, Menendez P, et al. Human embryonic stem cells maintained in the absence of mouse embryonic fibroblasts or conditioned media are capable of hematopoietic development. Blood 2005; 105:4598-603.
35. Manabe A, Murti KG, Coustan-Smith E, et al. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 1994;83:758-66.
36. Kim CH, Broxmeyer HE. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 1999;65:6-15.
37. De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 2005;5:805-24.
38. le Coutre P, Mologni L, Cleris L, et al. In vivo Eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999;91: 163-8.
39. Bradstock K, Bianchi A, Makrynikola V, et al. Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma. Leukemia 1996;10:813-20.
40. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002;43: 461-6.
41. Wu S, Korte A, Kebelmann-Betzing C, et al. Interaction of bone marrow stromal cells with lymphoblasts and effects of predinsolone on cytokine expression. Leuk Res 2005;29:63-72.
42. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
43. Konopleva M, Konoplev S, Hu W, et al. M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002;16:1713-24.
44. Bradstock KF, Gottlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma 1995;18:1-16.
45. Hewson J, Bianchi A, Bradstock K, et al. Ultrastructural changes during adhesion and migration of pre-B lymphoid leukaemia cells within bone marrow stroma. Br J Haematol 1996;92:77-87.
46. Schneider P, Vasse M, Sbaa-Ketata E, et al. The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis. Leukemia 2001;7:1143-5.
47. Dorsey JF, Cunnick JM, Lanehart R, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002;16:1589-95.
48. Shen W, Bendall LJ, Gottlieb DJ, et al. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001;29:1439-47.
49. Bradstock KF, Makrynikola V, Bianchi A, et al. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia 2000;14:882-8.
50. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30.